Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection

Koolen, M. J. M.; Borst, M. A. J.; Horzinek, Marian C.; Spaan, Willy J. M.

doi:10.1128/jvi.64.12.6270-6273.1990

Cited by 41 publications

(24 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, chickens vaccinated with the purified peplomer S were not protected against virulent IBV challenge [8]. The peplomer S of murine hepatitis virus (MHV), another coronavirus, was shown to carry determinants for induction of protective immunity [11,16,21]. Mice immunized with the purified peplomer S, containing the $1 and $2 glycoproteins, were protected from mortalities following virulent challenge.…”

Section: Introductionmentioning

confidence: 99%

“…Mice immunized with the purified peplomer S, containing the $1 and $2 glycoproteins, were protected from mortalities following virulent challenge. Immunization with synthetic peptides homologous to two conserved regions in the $2 glycoprotein of the peplomer S of MHV protected mice from virulent challenge, indicating that the protective epitopes might be located on the $2 glycoprotein of the peplomer S [21,32]. The $2 glycoprotein, which anchors the S1 glycoprotein of the peplomer to the viral membrane, may in IBV, carry also epitopes for crossreactive ELISA and weak VN antibodies [23,24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens

Ignjatovic

Galli

1994

Archives of Virology

152

147

View full text Add to dashboard Cite

The S1, N and M proteins, obtained from the nephropathogenic N1/62 strain of infectious bronchitis virus (IBV) by immunoaffinity purification with monoclonal antibodies, were used for immunization of chickens. For all three antigens multiple immunizations were necessary for induction of an antibody response. Protection of chickens vaccinated with the S1 glycoprotein against virulent challenge was demonstrated by the complete absence of virus in tracheas and kidneys of vaccinated chickens. Following four immunizations with the S1 glycoprotein 71% and 86% of chickens were protected at the level of tracheas and kidneys, respectively. Three immunizations with the S1 glycoprotein protected 70% and 10% of chickens at the level of kidney and trachea, respectively. Neither the N nor the M antigen induced protection to a virulent challenge with the nephropathogenic N1/62 strain of IBV after four immunizations. Virus neutralizing, haemagglutination inhibiting and ELISA antibodies were detected in chickens immunized with the S1 glycoprotein and inactivated N1/62 virus, however there was no correlation between the presence of any of these antibodies and protection.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens

Ignjatovic

Galli

1994

Archives of Virology

152

147

View full text Add to dashboard Cite

show abstract

“…Thus, most infected individuals recover from SARS. Furthermore, the success of a vaccine against other mammal-infective coronaviruses is encouraging [53,54]. Modern antiviral vaccine development depends heavily on the viral genome.…”

Section: Sars-cov Enzymes As Targets For Antiviral Agentsmentioning

confidence: 99%

From genome to antivirals: SARS as a test tube

Kliger

Levanon

Gerber

2005

Drug Discovery Today

View full text Add to dashboard Cite

The severe acute respiratory syndrome (SARS) epidemic brought into the spotlight the need for rapid development of effective anti-viral drugs against newly emerging viruses. Researchers have leveraged the 20-year battle against AIDS into a variety of possible treatments for SARS. Most prominently, based solely on viral genome information, silencers of viral genes, viral-enzyme blockers and viral-entry inhibitors were suggested as potential therapeutic agents for SARS. In particular, inhibitors of viral entry, comprising therapeutic peptides, were based on the recently launched anti-HIV drug enfuvirtide. This could represent one of the most direct routes from genome sequencing to the discovery of antiviral drugs.

show abstract

“…Epitopes are easily delivered in the context of DNA or viral vectors. An epitope-driven approach to coronavirus vaccine development has already been attempted with some success [48]. One advantage of the epitope based approach is that any region of the SARS-CoV genome that may be similar to self and therefore associated with a potential for autoimmune effects-can be eliminated.…”

Section: Epitope-based Vaccinesmentioning

confidence: 99%

How the SARS vaccine effort can learn from HIV?speeding towards the future, learning from the past

Groot

2003

Vaccine

View full text Add to dashboard Cite

A remarkable collaborative effort coordinated by the severe acute respiratory syndrome (SARS) team at WHO resulted in discovery of the etiologic agent of severe acute respiratory syndrome less than 2 months after the announcement of global alert. The development of a vaccine to prevent SARS should be pursued with the same urgency and cooperative spirit, as SARS is highly lethal and, if not controlled during the first few generations of transmission, is likely to become endemic in regions of the world where health-care infrastructure is underdeveloped and epidemiological control measures are weak. The scientific community already learned many important lessons from HIV vaccine development; these should be heeded. For example, consideration should be given to the development of a vaccine that will protect across regional strains of SARS, as the newly emergent coronavirus SARS-coronavirus (SARS-CoV) is proving to be variable and may be mutating in response to immune pressure. SARS-specific research reagents should also be collected and shared. These would include SARS peptides, adjuvants, DNA vaccine vectors and clinical grade viral vectors. Rapidly developing a collaborative approach to developing a SARS vaccine that will be both effective and safe is the only way to go. This article reviews parallels between HIV and SARS and proposes an approach that would accelerate the development of a SARS vaccine.

show abstract

Immunogenic peptide comprising a mouse hepatitis virus A59 B-cell epitope and an influenza virus T-cell epitope protects against lethal infection

Abstract: The coronavirus spike protein S is responsible for important biological activities including virus neutralization by antibody, cell attachment, and cell fusion. Recently, we have elucidated the amino acid sequence of an S determinant common in murine coronaviruses (W.

Cited by 41 publications

References 25 publications

The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens

The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens

From genome to antivirals: SARS as a test tube

How the SARS vaccine effort can learn from HIV?speeding towards the future, learning from the past

Contact Info

Product

Resources

About